z-logo
Premium
Heterologous expression of the biosynthetic gene clusters of coumermycin A 1 , clorobiocin and caprazamycins in genetically modified Streptomyces coelicolor strains
Author(s) -
Flinspach Katrin,
Westrich Lucia,
Kaysser Leonard,
Siebenberg Stefanie,
GomezEscribano Juan Pablo,
Bibb Mervyn,
Gust Bertolt,
Heide Lutz
Publication year - 2010
Publication title -
biopolymers
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.556
H-Index - 125
eISSN - 1097-0282
pISSN - 0006-3525
DOI - 10.1002/bip.21493
Subject(s) - streptomyces coelicolor , heterologous , chemistry , heterologous expression , streptomyces , biosynthesis , strain (injury) , biochemistry , gene , stereochemistry , bacteria , biology , genetics , mutant , recombinant dna , anatomy
The biosynthetic gene clusters of the aminocoumarin antibiotics clorobiocin and coumermycin A 1 and of the liponucleoside antibiotic caprazamycin were stably integrated into the genomes of different host strains derived from Streptomyces coelicolor A3(2). For the heterologous expression of clorobiocin derivatives in a chemically defined medium, inclusion of 0.6% of the siloxylated ethylene oxide/propylene oxide copolymer Q2‐5247 into the growth medium proved to result in a 4.8‐fold increase of productivity. Presumably, this copolymer acts as an oxygen carrier. The additional inclusion of cobalt chloride (0.2–2 mg l −1 ) dramatically increased the percentage of the desired compound clorobiocin within the total produced clorobiocin derivatives. This is very likely due to a stimulation of a cobalamin‐dependent methylation reaction catalyzed by the enzyme CloN6 of clorobiocin biosynthesis. All three investigated host strains ( S. coelicolor M512, M1146 and M1154) gave similar production rates of total clorobiocin derivatives (on average, 158 mg l −1 in the presence of 0.6% Q2‐5247 and 0.2 mg l −1 CoCl 2 ). In contrast, heterologous production of caprazamycin derivatives was optimal in strain M1154 (amounts of 152 mg l −1 on average). © 2010 Wiley Periodicals, Inc. Biopolymers 93: 823–832, 2010.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom